s99

S-99 is a high purity chemical that targets ASK and is important for Immunology, Inflammation, Cancer research.

KMS99220 is an orally active Keap-1 activator that acts as an Nrf2 inhibitor protein. It enhances Nrf2 nuclear translocation, increases the expression of antioxidant enzymes (such as heme oxygenase-1) and proteasome subunit genes, and alleviates oxidative stress and protein aggregation damage. KMS99220 is applicable for research in Parkinson's disease (PD).

S9947 is a Kv1.5/IKur channel blocker, suppressing both cloned (Kv1.5) and native (IKur) cardiac potassium current.

KS99 is a dual inhibitor of BTK and tubulin polymerization.

GS-9901 is a selective, orally active and potent PI3Kδ inhibitor (IC50: 1 nM) for the study of non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

TES-991 is a potent and selective inhibitor of human α-Amino-β-carboxymuconate-ε-semialdehyde Decarboxylase (ACMSD), with an IC50 of 3 nM.

Inarigivir soproxil (SB9200) is an agonist of innate immunity that demonstrates effective antiviral activity against resistant hepatitis C virus (HCV) variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems.

MIPS-9922 is a potent and selective PI3Kβ inhibitor with antiplatelet activity. MIPS-9922 inhibited integrin αIIbβ3 activation and αIIbβ3 dependent platelet adhesion to immobilized vWF under high shear. MIPS-9922 also potently inhibited ADP-induced washe

Carbamic acid, methyl-, m-((2-propynyloxy)methoxy)phenyl ester is a bioactive chemical.

AS-99 is a first-in-class, potent, and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 μM, Kd= 0.89 μM) with anti-leukemic activity, blocking cell proliferation, inducing apoptosis and differentiation, downregulating MLL fusion target genes, and reducing the leukemia burden in vivo[1].

AS-99 TFA is a potent, and selective ASH1L histone methyltransferase inhibitor with an IC50 of 0.79 μM. It exhibits robust anti-leukemic activity by blocking cell proliferation, inducing apoptosis and differentiation. AS-99 TFA exerts its effects by downregulating MLL fusion target genes and has been shown to significantly reduce leukemia burden in vivo.

Entospletinib (GS-9973) is a Syk inhibitor (IC50=7.7 nM) with selective, oral activity. Entospletinib has potential value in the treatment of a variety of hematological malignancies and immune-related diseases.

L6H9 is a novel inhibitor of myeloid differentiation factor 2 (MD2), suppressing HG-induced expression of ACE and AT1 receptor and Angiotensin II (AngII) production in renal NRK‐52E cells, resulting in the decrease in fibrosis markers such as TGF-β and collagen IV.

AS-99 is a first-in-class, potent, and selective inhibitor of the ASH1L histone methyltransferase, displaying anti-leukemic activity with an IC50 of 0.79 µM and a Kd of 0.89 µM. It inhibits cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and effectively reduces leukemia burden [in vivo].